Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

NCT ID: NCT05295459

Last Updated: 2025-05-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

182 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-13

Study Completion Date

2025-04-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multicenter, phase III, randomized, blinded, controlled, parallel group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 24-week, multicenter, phase III, randomized, blinded, controlled, parallel group with a 24-week treatment period to evaluate the efficacy and safety of LYR-210 compared with sham control for treatment in adults with CRS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Sinusitis Chronic Rhinosinusitis (Diagnosis)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LYR-210

Single administration of LYR-210 drug matrix (7500 μg)

Group Type EXPERIMENTAL

LYR-210

Intervention Type DRUG

LYR-210 drug matrix (mometasone furoate)

Background therapy

Intervention Type OTHER

Daily Saline Irrigation

Sham procedure control

Single mock administration procedure

Group Type SHAM_COMPARATOR

Sham procedure control

Intervention Type DRUG

Sham procedure control

Background therapy

Intervention Type OTHER

Daily Saline Irrigation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LYR-210

LYR-210 drug matrix (mometasone furoate)

Intervention Type DRUG

Sham procedure control

Sham procedure control

Intervention Type DRUG

Background therapy

Daily Saline Irrigation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18
* Diagnosed as having CRS
* Bilateral ethmoid disease confirmed on CT
* Mean 3 cardinal symptom (3CS) score
* Undergone at least 2 trials of medical treatments in the past
* Has been informed of the nature of the study and provided written informed consent
* Agrees to comply with all study requirements
* If currently on a waiting list for sinonasal surgery, willing to be removed from the waiting list or have preplanned surgery date cancelled for the duration of the study. \[Note: this does not preclude a participant from receiving or being recommended for sinonasal surgery as rescue treatment during the study\].

Exclusion Criteria

* Inability to tolerate topical anesthesia
* Previous nasal surgery
* Presence of nasal polyp grade 2 or higher
* Seasonal allergic rhinitis
* Perennial rhinitis with symptoms that are well controlled by regular use of intranasal corticosteroids
* Severe asthma
* History or clinical evidence or suspicion of invasive fungal sinusitis, allergic fungal rhinosinusitis, atrophic rhinitis, or odontogenic sinusitis
* Obstruction preventing proper placement and retention of LYR-210 as seen on endoscopy
* Anatomic variation that, in the opinion of the investigator, would adversely impact placement of LYR-210 as seen on CT
* Known history of hypersensitivity or intolerance to corticosteroids
* Known history of hypothalamic pituitary adrenal axial dysfunction
* Previous pituitary or adrenal surgery
* Dental procedure/implant on maxillary dentition within 4 weeks of the Screening visit.
* Past or present acute or chronic intracranial or orbital complications of CRS
* History or diagnosis (in either eye) of glaucoma or ocular hypertension
* Past or present functional vision in only 1 eye
* Past, present, or planned organ transplant or chemotherapy with immunosuppression
* Currently positive for COVID-19 or residual sinonasal symptoms from a previous COVID-19 infection
* Pregnant or breast feeding. Females of child-bearing potential must test negative for pregnancy at the time of screening
* Evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments
* Currently participating in an investigational drug or device study
* Determined by the investigator as not suitable to be enrolled
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lyra Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novak Clinical Trials

Tucson, Arizona, United States

Site Status

Keck School of Medicine at USC Medical Center

Arcadia, California, United States

Site Status

Sensa Health Clinical Research

Los Angeles, California, United States

Site Status

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

University of California - Irvine Medical Center

Orange, California, United States

Site Status

Sacramento Ear Nose and Throat Surgical and Medical Group, Inc

Roseville, California, United States

Site Status

University of California - Davis

Sacramento, California, United States

Site Status

Regional Head & Neck Consulting - SENTA Clinic

San Diego, California, United States

Site Status

Breathe Clear Institute

Torrance, California, United States

Site Status

Colorado ENT and Allergy

Colorado Springs, Colorado, United States

Site Status

Ear, Nose and Throat Associates of South Florida, P.A.

Boynton Beach, Florida, United States

Site Status

ENT and Allergy Associates of Florida - Brandon

Brandon, Florida, United States

Site Status

ENT and Allergy Associates of Florida - Plantation - Dr. Johnson

Plantation, Florida, United States

Site Status

ENT and Allergy Associates of Florida - Plantation - Dr. Wright

Plantation, Florida, United States

Site Status

ENT and Allergy Associates of Florida

Port Saint Lucie, Florida, United States

Site Status

The University of Chicago Medical Center (UCMC)

Chicago, Illinois, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

University of Kansas Medical Center (KUMC)

Fairway, Kansas, United States

Site Status

Tandem Clinical Research

Marrero, Louisiana, United States

Site Status

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, United States

Site Status

University of Missouri-Columbia

Columbia, Missouri, United States

Site Status

St Louis University

St Louis, Missouri, United States

Site Status

ENT and Allergy Associates, LLP - Fifth Avenue New York

New York, New York, United States

Site Status

Columbia University

New York, New York, United States

Site Status

University of Rochester

Rochester, New York, United States

Site Status

ENT and Allergy Associates - White Plains

White Plains, New York, United States

Site Status

Carolina Ear, Nose, & Throat Clinic/CENTRI, Inc.

Orangeburg, South Carolina, United States

Site Status

Houston Methodist Hospital

Houston, Texas, United States

Site Status

ENT Associates of Texas

McKinney, Texas, United States

Site Status

Lyra Investigational Site

Ogden, Utah, United States

Site Status

Lyra Investigational Site

Richmond, Virginia, United States

Site Status

University Hospital Gent

Ghent, , Belgium

Site Status

Universitaire Ziekenhuizen Leuven

Leuven, , Belgium

Site Status

University Multiprofile Hospital for Active Treatment

Burgas, , Bulgaria

Site Status

UMHAT Kaspela Ltd

Plovdiv, , Bulgaria

Site Status

Military Medical Academy Multiprofile Hospital

Sofia, , Bulgaria

Site Status

Diagnostic and Consulting Center Mladost - Varna

Varna, , Bulgaria

Site Status

HNO Praxis Dr. Andrea Kienle-Gogolok

Baden, , Germany

Site Status

HNO Zentrum am Kudamm

Berlin, , Germany

Site Status

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden, , Germany

Site Status

HNO Landsberg

Landsberg, , Germany

Site Status

Universitaetsklinikum Tuebingen

Tübingen, , Germany

Site Status

Semmelweis Egyetem - Nyaksebeszeti Klinika

Budapest, , Hungary

Site Status

Budapesti Bajcsy-Zsilinszky Korhaz es Rendelointezet

Budapest, , Hungary

Site Status

Szent Imre Korhaz

Budapest, , Hungary

Site Status

Eszak-Pesti Centrumkorhaz - Honvedkorhaz

Budapest, , Hungary

Site Status

Budapesti Uzsoki Utcai Korhaz

Budapest, , Hungary

Site Status

Lyra Investigational Site

Nyíregyháza, , Hungary

Site Status

Pecsi Tudomanyegyetem Klinikai Kozpont

Pécs, , Hungary

Site Status

Komarom-Esztergom Varmegyei Szent Borbala Korhaz

Tatabánya, , Hungary

Site Status

Sleepmedica

Bialystok, , Poland

Site Status

"Farma-Med." Kujawskie Centrum Medyczne Sp. z o.o.

Inowrocław, , Poland

Site Status

Promed P.Lach R.Glowacki Spolka Jawna

Krakow, , Poland

Site Status

Velocity Lublin

Lublin, , Poland

Site Status

Mazowiecki Szpital Brodnowski Sp. z o.o. - Zespol Oddzialow Otolaryngologii

Warsaw, , Poland

Site Status

Lyra Investigational Site

Warsaw, , Poland

Site Status

Panstwowy Instytut Medyczny MSWiA - Klinika Otolaryngologii

Wroclaw, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Bulgaria Germany Hungary Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LYR-210-2021-005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NEUROMARK Randomized Controlled Trial
NCT06128200 ACTIVE_NOT_RECRUITING NA
NasoNeb Delivery of an Intranasal Steroid
NCT01270256 COMPLETED PHASE4
Erenumab for Idiosyncratic Facial Pain
NCT04249427 COMPLETED PHASE4
480 Biomedical Sinus Drug Depot
NCT02967731 COMPLETED PHASE1
Laser Posterior Nasal Nerve Neurolysis
NCT07050992 ACTIVE_NOT_RECRUITING NA